ADC Therapeutics SA Cash Flows From Used In Investing Activities
ADC Therapeutics SA (ADCT) reported Cash Flows From Used In Investing Activities of -$2.69 million for the 9-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Cash Flow › Investing Activities
ifrs-full:CashFlowsFromUsedInInvestingActivities · last filed 2023-11-07
- ADC Therapeutics SA cash flows from used in investing activities for the quarter ending 2023-09-30 was -$661.00K.
- ADC Therapeutics SA cash flows from used in investing activities for the quarter ending 2023-06-30 was -$1.01M.
- ADC Therapeutics SA cash flows from used in investing activities for the quarter ending 2023-03-31 was -$1.02M.
- ADC Therapeutics SA cash flows from used in investing activities for the quarter ending 2022-12-31 was -$117.00K.
| Period end | Cash Flows From Used In Investing Activities 3 month | Cash Flows From Used In Investing Activities 6 month | Cash Flows From Used In Investing Activities 9 month | Cash Flows From Used In Investing Activities 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$661.00K derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07 | -$1.67M derived: sum of 2 quarters · filed 2023-11-07 | -$2.69M 6-K · filed 2023-11-07 | -$2.81M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | -$1.01M derived: 6-K 6 month − 6-K 3 month · filed 2023-08-08 | -$2.03M 6-K · filed 2023-08-08 | -$2.15M derived: sum of 3 quarters · filed 2023-08-08 | -$2.40M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | -$1.02M 6-K · filed 2023-05-09 | -$1.13M derived: sum of 2 quarters · filed 2023-05-09 | -$1.39M derived: sum of 3 quarters · filed 2023-11-07 | -$2.08M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | -$117.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | -$371.00K derived: sum of 2 quarters · filed 2023-11-07 | -$1.06M derived: sum of 3 quarters · filed 2023-11-07 | -$2.51M 20-F · filed 2023-03-15 |
| 2022-09-30 | -$254.00K derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07 | -$943.00K derived: sum of 2 quarters · filed 2023-11-07 | -$2.39M 6-K · filed 2023-11-07 | -$3.22M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$689.00K derived: 6-K 6 month − 6-K 3 month · filed 2023-08-08 | -$2.14M 6-K · filed 2023-08-08 | -$2.97M derived: sum of 3 quarters · filed 2023-08-08 | -$5.30M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$1.45M 6-K · filed 2023-05-09 | -$2.28M derived: sum of 2 quarters · filed 2023-05-09 | -$4.62M derived: sum of 3 quarters · filed 2023-05-09 | -$7.46M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$830.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | -$3.17M derived: sum of 2 quarters · filed 2023-03-15 | -$6.02M derived: sum of 3 quarters · filed 2023-03-15 | -$6.67M 20-F · filed 2023-03-15 |
| 2021-09-30 | -$2.34M derived: 6-K 9 month − 6-K 6 month · filed 2022-11-08 | -$5.19M derived: sum of 2 quarters · filed 2022-11-08 | -$5.84M 6-K · filed 2022-11-08 | -$6.64M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | -$2.85M derived: 6-K 6 month − 6-K 3 month · filed 2022-08-09 | -$3.50M 6-K · filed 2022-08-09 | -$4.30M derived: sum of 3 quarters · filed 2023-03-15 | -$5.70M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | -$657.00K 6-K · filed 2022-05-09 | -$1.45M derived: sum of 2 quarters · filed 2023-03-15 | -$2.85M derived: sum of 3 quarters · filed 2023-03-15 | -$2.99M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | -$793.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | -$2.19M derived: sum of 2 quarters · filed 2023-03-15 | -$2.33M derived: sum of 3 quarters · filed 2023-03-15 | -$2.83M 20-F · filed 2023-03-15 |
| 2020-09-30 | -$1.40M derived: 6-K 9 month − 6-K 6 month · filed 2021-11-02 | -$1.54M derived: sum of 2 quarters · filed 2021-11-02 | -$2.04M 6-K · filed 2021-11-02 | |
| 2020-06-30 | -$138.00K derived: 6-K 6 month − 6-K 3 month · filed 2021-08-03 | -$634.00K 6-K · filed 2021-08-03 | ||
| 2020-03-31 | -$496.00K 6-K · filed 2021-05-06 | |||
| 2019-12-31 | -$2.25M 20-F · filed 2022-03-17 | |||
| 2018-12-31 | -$2.51M 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |